PROTAC (proteolysis-targeting chimeras), which selectively degrades target proteins, has
become the most popular technology for drug development in recent years. Here, we …

Herein, we describe a systematic SAR‐and SPR‐investigation of the peptidomimetic
hydroxy‐proline based VHL‐ligand VH032, from which most to‐date published VHL …

The off-target toxicity of drugs targeted to proteins imparts substantial health and economic
costs. Proteome interaction studies can reveal off-target effects with unintended proteins; …

Targeted protein degradation technology has evolved a brand-new therapeutic modality
from an innovative drug discovery perspective. Though the classical PROTACs has …

MicroRNA (miRNA) has been widely used as an effective gene drug for tumor therapy, but
its chemical instability limited its therapeutic application in vivo. In this research, we fabricate …

Cancer immunotherapy using immune-checkpoint inhibitors (ICIs) has revolutionized the
field of cancer treatment; however, ICI efficacy is constrained by progressive dysfunction of …

The pandemic caused by SARS-CoV-2 has called for concerted efforts to generate new
insights into the biology of betacoronaviruses to inform drug screening and development …

Ribonucleases (RNases) cleave and process RNAs, thereby regulating the biogenesis,
metabolism, and degradation of coding and noncoding RNAs. Thus, small molecules …

Although fragment-based drug discovery (FBDD) has been successfully implemented and
well-explored for protein targets, its feasibility for RNA targets is emerging. Despite the …

Introduction The field of RNA-targeted small molecules is rapidly evolving, owing to the
advances in experimental and computational technologies. With the identification of several …